A Study of Baricitinib (LY3009104) in Children From 6 Years to Less Than 18 Years of Age With Alopecia Areata

NCT05723198 · clinicaltrials.gov ↗

PHASE3

Phase

RECRUITING

Status

595

Enrollment

INDUSTRY

Sponsor class

Conditions

Areata Alopecia
Alopecia
Hypotrichosis
Hair Diseases
Skin Diseases
Pathological Conditions, Anatomical

Interventions

DRUG: Baricitinib
DRUG: Placebo

Sponsor

Eli Lilly and Company